Hair Loss Treatment Biotech Companies Eye Growth as New Therapies Approach

Biotech companies focused on hair loss treatments are racing to develop new therapies as nearly 30 years pass without a major breakthrough in the field. Investors are positioning themselves in anticipation of future profits.
Vedermix, Axsi, and Cosmo Pharmaceuticals are developing oral medications, injectables, and topical solutions respectively for male pattern baldness. No new treatments have been approved since the late 1990s for this condition.
According to Bloomberg, male pattern baldness affects approximately 50 million men and 30 million women in the U.S. Current treatment options remain limited to decades-old medications like minoxidil and finasteride, which are associated with side effects including heart palpitations and decreased libido.
Vedermix (NYSE: MANE) is developing an oral medication called VDPHL01. The company's stock has surged approximately 500% since its February IPO. Axsi (NASDAQ: ABSI) is testing a biweekly injectable treatment, with shares more than doubling this year. Cosmo Pharmaceuticals reported positive results in late-stage clinical trials for its topical solution but appears to be taking a cautious approach compared to U.S. competitors.
This market enthusiasm echoes the recent surge in Eli Lilly's stock, which has risen nearly 350% over five years largely driven by GLP-1 drugs Zepbound and Mounjaro. Eli Lilly has invested $40 million in Axsi, reflecting expectations that hair loss treatments could follow a similar injectable-based growth strategy.
None of the three companies have approved products yet, with the earliest regulatory submissions not expected before 2027. Investors are already pricing future demand into stock valuations years ahead of potential product launches.
Korean Source
This article is an English localization of a Korean-language crypto news report. Original headline: 탈모 치료 바이오텍, 월가 차세대 성장주